{"id":"NCT01223365","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time","officialTitle":"A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours in Patients Who Require Opioid Treatment for an Extended Period of Time","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2010-10-19","resultsPosted":"2017-04-05","lastUpdate":"2017-06-05"},"enrollment":330,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Pain"],"interventions":[{"type":"DRUG","name":"Hydrocodone ER","otherNames":["CEP-33237","Hydrocodone bitartrate extended-release"]}],"arms":[{"label":"Hydrocodone ER","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the safety of hydrocodone extended-release tablets when used over a 12-month period in patients with chronic pain, as assessed by adverse events, clinical laboratory results, vital signs measurements, electrocardiogram results, physical examination findings, pure tone audiometry, and concomitant medication usage.","primaryOutcome":{"measure":"Participants With Adverse Experiences","timeFrame":"Day 1 of open-label titration period - Week 52 of the open-label treatment period","effectByArm":[{"arm":"New Opioid Na√Øve Subpopulation","deltaMin":51,"sd":null},{"arm":"New Opioid Experienced Subpopulation","deltaMin":98,"sd":null},{"arm":"Rollover Subpopulation","deltaMin":135,"sd":null},{"arm":"Total Hydrocodone ER","deltaMin":284,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":54,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":52},"commonTop":["Constipation","Nausea","Headache","Somnolence","Vomiting"]}}